We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+16.2%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$126M
AUM Growth
+$27.3M
Cap. Flow
+$10M
Cap. Flow %
7.93%
Top 10 Hldgs %
54.03%
Holding
70
New
10
Increased
16
Reduced
10
Closed
7

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$3.68M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$3.29M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$2.09M
4
EVFM
Evofem Biosciences, Inc. Common Stock
EVFM
+$1.56M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$1.51M

Top Sells

Rank Stock Value
1
XNPT
XENOPORT, INC.
XNPT
+$1.04M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$1.04M
3
BSTC
BioSpecifics Technologies Corp.
BSTC
+$1.01M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$683K
5
VCEL icon
Vericel Corp
VCEL
+$681K

Sector Composition

Rank Sector Weight
1 Healthcare 60.28%
2 Financials 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GYRE icon
26
Gyre Therapeutics
GYRE
$629M
$1.22M 0.97%
591
+421
+248% +$811K
RIOT icon
27
Riot Platforms
RIOT
$6.9B
$1.17M 0.92%
82,250
– –
BLUE
28
DELISTED
bluebird bio
BLUE
$1.15M 0.91%
965
-965
-50% -$645K
CRDC
29
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$1.04M 0.82%
148,600
– –
UPI
30
DELISTED
UROPLASTY INC-NEW
UPI
$1M 0.79%
486,062
– –
JNJ icon
31
Johnson & Johnson
JNJ
$640B
$983K 0.78%
9,400
– –
CYTR
32
DELISTED
CytRx Corp
CYTR
$949K 0.75%
57,733
+20,233
+54% +$316K
CUTR
33
DELISTED
Cutera, Inc.
CUTR
$947K 0.75%
88,694
– –
GLMD icon
34
Galmed Pharmaceuticals
GLMD
$4.62M
$917K 0.73%
878
+228
+35% +$248K
ECI
35
DELISTED
ENCISION INC
ECI
$882K 0.7%
1,062,500
– –
XNPT
36
DELISTED
XENOPORT, INC.
XNPT
$861K 0.68%
98,190
-142,000
-59% -$1.04M
ELOS
37
DELISTED
Syneron Medical Ltd
ELOS
$849K 0.67%
90,947
– –
EXAC
38
DELISTED
Exactech Inc
EXAC
$746K 0.59%
31,636
– –
AFMD
39
DELISTED
Affimed
AFMD
$744K 0.59%
12,000
– –
CDNA icon
40
CareDx
CDNA
$1.83B
$633K 0.5%
87,300
+12,300
+16% +$82.5K
IPCI
41
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$631K 0.5%
27,926
+20,647
+284% +$558K
QURE icon
42
uniQure
QURE
$2.78B
$587K 0.46%
39,656
+7,656
+24% +$93.7K
SRGA
43
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$447K 0.35%
2,864
– –
GNVC
44
DELISTED
GenVec, Inc.
GNVC
$416K 0.33%
20,000
+10,000
+100% +$193K
VANI icon
45
Vivani Medical
VANI
$109M
$408K 0.32%
+1,658
New +$578K
APEN
46
DELISTED
Apollo Endosurgery, Inc.
APEN
$344K 0.27%
1,583
+248
+19% +$55.4K
FATE icon
47
Fate Therapeutics
FATE
$275M
$297K 0.23%
59,110
-16,820
-22% -$74.2K
LMNS
48
DELISTED
LUMENIS LTD CL B ORD SHS (ISR)
LMNS
$290K 0.23%
31,072
+2,054
+7% +$19.4K
NSPH
49
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$235K 0.19%
+30,000
New +$280K
AKTX
50
Akari Therapeutics
AKTX
$14.4M
$211K 0.17%
5
– –
1
2
3

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, DAFNA Capital Management held 70 positions worth $126M, up 27% from $99.1M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

DAFNA Capital Management deployed $10M of net new capital in Q4 2014, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was CTI BioPharma Corp. (DE) Common Stock: 142,500 shares worth $3.36M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 56% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was XENOPORT, INC., an estimated $1.04M trimmed.

  • DAFNA Capital Management's largest Q4 2014 buy was CTI BioPharma Corp. (DE) Common Stock: 142,500 shares worth $3.36M.
  • DAFNA Capital Management added most to Intercept Pharmaceuticals, Inc. in Q4 2014, an estimated $3.68M increase.
  • DAFNA Capital Management's biggest Q4 2014 reduction was XENOPORT, INC., cutting an estimated $1.04M.
  • DAFNA Capital Management fully exited Neurocrine Biosciences in Q4 2014, selling an estimated $1.04M.
  • DAFNA Capital Management's ten largest holdings make up 54% of its $126M portfolio in Q4 2014.
  • DAFNA Capital Management opened 10 new positions and closed 7 in Q4 2014.
  • DAFNA Capital Management's portfolio value rose 27% quarter-over-quarter to $126M.

Based on DAFNA Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.